BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16302103)

  • 1. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
    Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
    Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of liposome-encapsulated antimony in dogs.
    Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
    Braz J Med Biol Res; 2003 Feb; 36(2):269-72. PubMed ID: 12563530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
    Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
    Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
    Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
    Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
    Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.
    da Silva SM; Amorim IF; Ribeiro RR; Azevedo EG; Demicheli C; Melo MN; Tafuri WL; Gontijo NF; Michalick MS; Frézard F
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2858-67. PubMed ID: 22411610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
    Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
    Valladares JE; Alberola J; Esteban M; Arboix M
    Vet Rec; 1996 Feb; 138(8):181-3. PubMed ID: 8677619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs.
    Valladares JE; Freixas J; Alberola J; Franquelo C; Cristofol C; Arboix M
    Am J Trop Med Hyg; 1997 Oct; 57(4):403-6. PubMed ID: 9347953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
    Chapman WL; Hanson WL; Alving CR; Hendricks LD
    Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
    Gramiccia M; Gradoni L; Orsini S
    Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate.
    Ikeda-Garcia FA; Lopes RS; Marques FJ; de Lima VM; Morinishi CK; Bonello FL; Zanette MF; Perri SH; Feitosa MM
    Vet Parasitol; 2007 Feb; 143(3-4):254-9. PubMed ID: 16996214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel methods for the encapsulation of meglumine antimoniate into liposomes.
    Frézard F; Michalick MS; Soares CF; Demicheli C
    Braz J Med Biol Res; 2000 Jul; 33(7):841-6. PubMed ID: 10881061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
    Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
    Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
    Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
    Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
    Belloli C; Crescenzo G; Carli S; Zaghini A; Mengozzi G; Bertini S; Ormas P
    Vet J; 1999 May; 157(3):315-21. PubMed ID: 10328843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size.
    Schettini DA; Ribeiro RR; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
    Int J Pharm; 2006 Jun; 315(1-2):140-7. PubMed ID: 16549281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
    Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
    Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.